Flamingo Therapeutics

👥 20 employees💰 Last funded Mar 2023
Biotechnology Research🌐 flamingotx.com
Website LinkedIn
Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, funds managed by Tekla Capital Management LLC and VIB.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Belgium
1
France
1
Frequently asked questions
Who invested in Flamingo Therapeutics?
Flamingo Therapeutics has 2 investors on record on gritt.io.
When did Flamingo Therapeutics last raise funding?
The most recent investment in Flamingo Therapeutics recorded on gritt.io was in March 2023.
What industry is Flamingo Therapeutics in?
Flamingo Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.